Daniel de Boer, ProQR CEO (via YouTube)
August 11, 2022 10:50 AM EDTUpdated 04:54 PM
R&D

Just months af­ter lay­offs and push­ing eye ther­a­py, Pro­QR to of­fload eye port­fo­lio in piv­ot to RNA-edit­ing

Paul Schloesser

Associate Editor

Near­ly four months af­ter join­ing dozens of oth­er biotechs in lay­ing off em­ploy­ees and trim­ming down its pipeline, Pro­QR is back at it again. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

A service from the Financial Times